Nikki Mathis

Principal at Amgen, Inc.

Nikki Mathis

Nikki Mathis

Principal at Amgen, Inc.

Overview
RelSci Relationships

1611

Relationships
RelSci Relationships are individuals Nikki Mathis likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman & Chief Executive Officer at Amgen, Inc.

Relationship likelihood: Average

Executive Director & Head of Global Media Relations at Amgen, Inc.

Relationship likelihood: Average

Executive Director at Amgen, Inc.

Relationship likelihood: Average

Executive Director, Global Oncology Marketing at Amgen, Inc.

Relationship likelihood: Average

Founder at Amgen, Inc.

Relationship likelihood: Average

System Owner at Amgen, Inc.

Relationship likelihood: Average

Owner at Amgen, Inc.

Relationship likelihood: Average

Executive Director of Biometrics at Amgen, Inc.

Relationship likelihood: Average

Executive Director Regional Sales at Amgen, Inc.

Relationship likelihood: Average

AML 14 Executive Director at Amgen, Inc.

Relationship likelihood: Average

Paths to Nikki Mathis
Potential Connections via
Relationship Science
You
Nikki Mathis
Principal at Amgen, Inc.
Career History
Principal
Tenure Unconfirmed

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Other Affiliations

Nikki Mathis is affiliated with Amgen, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nikki Mathis. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nikki Mathis's profile does not indicate a business or promotional relationship of any kind between RelSci and Nikki Mathis.